Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Akero Therapeutics Inc (NQ: AKRO ) 28.83 +0.14 (+0.49%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 634,760 Open 28.51 Bid (Size) 28.83 (1) Ask (Size) 28.86 (11) Prev. Close 28.69 Today's Range 27.65 - 28.88 52wk Range 11.25 - 51.24 Shares Outstanding 50,086,978 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference September 30, 2024 From Akero Therapeutics Inc. Via GlobeNewswire AKERO THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc. - AKRO September 20, 2024 From Kahn Swick & Foti, LLC Via Business Wire Performance YTD +22.79% +22.79% 1 Month +10.93% +10.93% 3 Month +24.48% +24.48% 6 Month +19.78% +19.78% 1 Year -37.02% -37.02% More News Read More Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session September 12, 2024 Via Benzinga Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH September 09, 2024 From Akero Therapeutics Inc. Via GlobeNewswire Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference August 28, 2024 From Akero Therapeutics Inc. Via GlobeNewswire AKERO THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc. - AKRO August 26, 2024 From Kahn Swick & Foti, LLC Via Business Wire AKRO Stock Earnings: Akero Therapeutics Beats EPS for Q2 2024 August 09, 2024 Via InvestorPlace Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update August 09, 2024 From Akero Therapeutics Inc. Via GlobeNewswire This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges July 15, 2024 Via Benzinga Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm June 28, 2024 From Lowey Dannenberg, P.C. Via GlobeNewswire AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm June 25, 2024 From The Schall Law Firm Via Business Wire The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO) June 24, 2024 From The Law Offices of Frank R. Cruz Via Business Wire AKRO FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – AKRO June 24, 2024 From The Rosen Law Firm PA Via GlobeNewswire Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm June 24, 2024 From Lowey Dannenberg, P.C. Via GlobeNewswire AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm June 24, 2024 From The Schall Law Firm Via Business Wire AKERO THERAPEUTICS 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO June 21, 2024 From Kahn Swick & Foti, LLC Via Business Wire Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm June 21, 2024 From Lowey Dannenberg, P.C. Via GlobeNewswire INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics June 21, 2024 From Faruqi & Faruqi LLP Via GlobeNewswire AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm June 21, 2024 From Schall Law Via GlobeNewswire ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – AKRO June 20, 2024 From The Rosen Law Firm PA Via GlobeNewswire Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm June 19, 2024 From Lowey Dannenberg, P.C. Via GlobeNewswire AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm June 18, 2024 From Schall Law Via GlobeNewswire Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm June 17, 2024 From Lowey Dannenberg, P.C. Via GlobeNewswire Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm June 13, 2024 From Lowey Dannenberg, P.C. Via GlobeNewswire INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics June 12, 2024 From Faruqi & Faruqi LLP Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.